News

The first agreement between the companies was announced in November 2002 and focused on drug targets for immunological diseases. This new agreement expands the collaboration scope and will

The new vaccine, named MOPV1, will be used first in Egypt as a critical part of a new World Health Organization (WHO) strategy to end polio transmission by

Asmanex Twisthaler 220mcg (mometasone furoate inhalation powder) is now approved for the first-line maintenance treatment of asthma as preventive therapy in patients 12 years of age and older.

The Dermatrends’ nonsteroidal anti-inflammatory drug (NSAID) patch has been tested extensively in vitro, indicating that drugs such as meloxicam can be delivered to match systemic blood level concentrations

PTC124 represents a first-in-class, orally delivered investigational new drug in development for the treatment of genetic disorders due to nonsense mutations. Nonsense mutations are single-point alterations in the

The approximate $19.7 million acquisition price was financed through non-dilutive, asset-based funding provided by Westernbank Business Credit Division of Westernbank Puerto Rico. The operations in Manati, Puerto Rico

In taking a public stand against the military’s investigational anthrax vaccine, the band makes it possible to reach huge numbers of the general public to inform them about

HuC242-DM4, ImmunoGen’s tumor-activated prodrug (TAP) compound, is in development for the treatment of CanAg-expressing cancers, such as gastrointestinal and non-small cell lung cancers. ImmunoGen’s TAP technology uses tumor-targeting

Mycamine (micafungin sodium), an antifungal in the echinocandin class, was approved by the FDA on March 16, 2005 for the treatment of patients with esophageal candidiasis and for